Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Nanoscale Research Letters|August 31, 2017
First-Principles Study on the Stability and STM Image of BoropheneZhifen Luo, Xiaoli Fan, Yurong An
Nanoscale Research Letters|June 6, 2019
Electronic and Magnetic Properties of Defected Monolayer WSe2 with VacanciesDanxi Yang, Xiaoli Fan, Fengxia Zhang, et al.
Nanoscale|June 22, 2023
Two-dimensional MN4 materials as effective multifunctional electrocatalysts for the hydrogen-evolution, oxygen-evolution, and oxygen-reduction reactionsXian Zhang, Zhifen Luo, Jiayi Fan, et al.
Oncology Letters|April 30, 2017
MicroRNA-146a affects the chemotherapeutic sensitivity and prognosis of advanced gastric cancer through the regulation of LIN52Zhifen Luo, Xiqing Li, Zunlan Zhao, et al.
The Journal of Physical Chemistry. B|March 2, 2023
Extension of the TraPPE Force Field for Battery Electrolyte SolventsZhifen Luo, Stephen A Burrows, Stoyan K Smoukov, et al.
Pakistan Journal of Pharmaceutical Sciences|October 19, 2017
Expression and significance of DDX43 in lung adenocarcinomaNing Ma, Hua-En Xu, Zhifen Luo, et al.
Frontiers in Oncology|March 20, 2025
Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapyYingbo Shao, Huijuan Guan, Zhifen Luo, et al.
Frontiers in Oncology|August 15, 2022
A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancerYingbo Shao, Zhifen Luo, Yang Yu, et al.
Breast (Edinburgh, Scotland)|December 30, 2023
Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapyYingbo Shao, Huijuan Guan, Zhifen Luo, et al.
Frontiers in Endocrinology|September 5, 2022
HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world studyYingbo Shao, Zhifen Luo, Yang Yu, et al.
Pageof 2